Recon: Takeda signs $2B gene therapy deal exploring AAV alternatives; Baxter warns of infusion pump problems tied to three deaths
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy